Dundee starts SQI Diagnostics at buy
November 2, 2009 by leonardzehr · Leave a Comment
The FDA has cleared marketing of SQI Diagnostics’ automated SQiDworks Diagnostics Platform and its lead IgXPLEX assay panel for rheumatoid arthritis in the U.S., prompting Dundee Securities to initiate coverage of the stock with a “buy” rating and a 12-month price target of $6. SQI (TSX-V:SQD) touched a 52-week high of $2.65 in early trading [...]
Listen to BioTuesdays 
